Senate Committee Closes Books On 2016 Pricing Investigation; PBMs In Hot Seat Next?
Executive Summary
US Senate Aging Committee wrapped up its investigation into price spikes for off-patent drugs with some relatively unsurprising (and – for most innovator companies – unthreatening) policy recommendations; a brief coda to the report offers two possible directions for future investigations: abuse of the patent system – or the impact of PBM practices.